Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GABRP | O00591 | 2/20 | 0.44 |
| ▸ | GABRD | O14764 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.44 |
| ▸ | GABRE | P78334 | 2/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.44 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demoxepam SCHEMBL29611580 | 1.00 | CNR1 (0.54) | CNR1NTSR1OPRK1PDE4DCYP1A2 | |
| SCHEMBL11632406 | 0.87 | CNR1 (0.41) | CNR1NTSR1OPRK1PDE4DCYP1A2 | |
| SCHEMBL11631409 | 0.87 | PSEN1 (0.44) | CNR1NTSR1OPRK1PDE4DCYP1A2 | |
| SCHEMBL6527541 | 0.86 | GABRA1 (0.55) | CNR1NTSR1OPRK1PDE4DCYP1A2 | |
| SCHEMBL32681120 | 0.86 | GABRA1 (0.55) | CNR1NTSR1OPRK1PDE4DCYP1A2 | |
| SCHEMBL2846056 | 0.84 | KMT2A (0.47) | CYP1A2KDM4EGABRA1GABRG2GABRB3 | |
| SCHEMBL11319239 | 0.84 | LMNA (0.57) | CNR1NTSR1OPRK1PDE4DGABRP | |
| SCHEMBL7306150 | 0.80 | CYP1A2 (0.42) | CNR1NTSR1OPRK1PDE4DCYP1A2 | |
| SCHEMBL7306143 | 0.80 | CYP1A2 (0.42) | CNR1NTSR1OPRK1PDE4DCYP1A2 | |
| Desipramine SCHEMBL7763271 | 0.79 | CYP3A4 (0.47) | CNR1NTSR1OPRK1PDE4DCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3863708-B1 | MIXED IONIC CONDUCTORS AND CORRESPONDING DEVICES, SYSTEMS AND METHODS OF MAKING | BATTELLE MEMORIAL INSTITUTE (US) | 2024-09-11 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-103796656-A | Administration of benzodiazepines | HALE BIOPHARMA VENTURES LLC | 2014-05-14 | — | — | CN | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| EP-2277584-A1 | Electrokinetic delivery device | Biophoretic Therapeutic Systems, LLC (US) | 2011-01-26 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20090220611-A1 | Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same | FLAMEL TECHNOLOGIES, S.A. (FR) | 2009-09-03 | — | — | US | claimed |
| EP-1455888-B1 | TOPICAL ADMINISTRATION DEVICE | PHARMAKODEX LTD (GB) | 2009-04-29 | — | — | EP | claimed |
| WO-2003018102-A2 | TOPICAL ADMINISTRATION DEVICE | VECTURA LIMITED (US) | 2003-03-06 | — | — | WO | claimed |
| US-6495154-B1 | ADMINISTERING ANTIDEPRESSANTS, ADRENERGIC STIMULANTS, SEROTONIN AGONISTS AND ANTAGONISTS AS THERAPEUTIC AGENTS FOR SEXUAL DISORDERS | VIVUS INC. | 2002-12-17 | — | — | US | claimed |
| US-20020161016-A1 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | VIVUS LLC (F/K/A VIVUS, INC.) | 2002-10-31 | — | — | US | claimed |
| US-20020151543-A1 | Compositions and methods employing R (-) fluoxetine and other active ingredients | SEPRACOR INC. | 2002-10-17 | — | — | US | claimed |
| WO-2002041883-A2 | AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION | VIVUS, INC. (US) | 2002-05-30 | — | — | WO | claimed |
| WO-2002005851-A2 | ENHANCEMENT OF THE ACTION OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM AGENTS | PITMY INTERNATIONAL N.V. (AN) | 2002-01-24 | — | — | WO | claimed |
| WO-1999061014-A2 | COMPOSITIONS AND METHODS EMPLOYING R(-) FLUOXETINE AND OTHER ACTIVE INGREDIENTS | SEPRACOR INC. (US) | 1999-12-02 | — | — | WO | claimed |
| US-5248678-A | Administering adenosine receptor antagonist and a GABA antagonist | FRACTAL LABORATORIES, INC. (US) | 1993-09-28 | — | — | US | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
| US-4083948-A | IODINE LABELS | HOFFMANN-LA ROCHE, INC. (US) | 1978-04-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161016-A1 | As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation | HTR5A, HTR1A, MAOA | CNR1 1040/4885NTSR1 483/4885OPRK1 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.